b'E x e c u t i v eL e a d e r s h i p Te a mJeffrey Edward Miller, Ph.D. Founder, Chief Scientific Officer, & Chief Executive OfficerDr. Miller is a scientist, inventor, and entrepreneur focused on Improving Lives with Precision Diagnosticscoupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB. Prior to starting Invivoscribe, Dr. Miller had more than twenty years of combined experience in protein biochemistry, cellular and molecular immunology, cardiac physiology, virology, and molecular biology, experience he had developed workingin laboratories at the Medical School, Department of Chemistry, Molecular Biology Institute at UCLA, while earning his Ph.D. at UCSB, and as a postdoctoral scientist at Applied Molecular Evolution. He also spent several years at Quest Diagnostics Jeffrey Edward MillerNichols Institute, setting up the molecular oncology laboratory and developing and launching PCR-based molecular assays for infectious disease and hematopathology.Meghna Bhatnagar, MBA Chief Financial OfficerMeghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology. Since her arrival,Ms. Bhatnagar has played an integral role in directing all aspects of company strategy, planning and operations.Ms. Bhatnagar has over 20 years of experience building and leading finance and IT teams in global companies. Prior to joining IVS, she served as COO of Radiant Technologies, a technology company focused on providing business management solutions to small and medium sized companies where she was responsible for leadership and development of an entire project delivery team with full P&L responsibility. She played a key role in guiding overall strategy of the company and at the Meghna Bhatnagar same time provided leadership for operational improvements.Tony Lialin Chief Commercial OfficerTony Lialin joined Invivoscribe in 2021 as Chief Commercial Officer. In this role he is responsible for leading the global commercial organization. Mr. Lialin has more than two decades of experience in growing companies in the life sciences industry having held positions in clinical diagnostic, bioinformatics software, instrumentation and reagent companies.He has successfully scaled commercial operations at three start-ups resulting in those companies being purchased by large public companies. Mr. Lialin comes to IVS from Loop Genomics, an NGS long-read sequencing company where he started their global commercial operations growing their business to several million dollars in revenue per year in just three years. From 2014 through June 2018, Mr. Lialin managed $400M in portfolio business at Illumina working closely with customersin the DTC, Oncology and Postnatal testing spaces. He also served as a director at Agilent Technologies, where he managed the emerging market, field application scientist, and technical support and field service engineering teams.As a six-sigma Tony Lialin green belt he values process, service as a differentiator and both internal and external customers. Mr. Lialin earneda BA in Molecular Cellular and Developmental Biology from the University of California at Santa Cruz.8'